In agreement with our findings, a study by Fadini et al. from a large multicenter real-world setting in Europe in which patients’ basal insulin was switched to insulin deglude found a significant HbA1c reduction of 0.32% in type 2 diabetes as well as a reduction in insulin requirements at the 12-month follow-up period [25]. The gene discussed is INS; the disease is type 2 diabetes mellitus.